(VIANEWS) – SOCIETE GENERALE (GLE.PA), ROCHE BOBOIS (RBO.PA), SUBSEA 7 (SUBC.OL) are the highest payout ratio stocks on this list.
We have collected information regarding stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SOCIETE GENERALE (GLE.PA)
101.92% Payout Ratio
Société Générale Société anonyme provides banking and financial services to individuals, businesses, and institutional investors in Europe and internationally. It operates through French Retail Banking, International Retail Banking & Financial Services, and Global Banking and Investor Solutions. It offers retail banking services, such as consumer credit, vehicle leasing and fleet management, online banking, wealth management services, and equipment and vendor finance under the Societe Generale, Credit du Nord, and Boursorama brand names; and insurance products, including home, vehicle, family, health, and mortgage insurance. The company also provides corporate and investment banking, securities, business consulting, consumer finance, advisory and financing, and asset management and private banking services. In addition, it offers brokerage, cash management, payment, factoring, export financing, and supply chain financing services. Société Générale Société anonyme was incorporated in 1864 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SOCIETE GENERALE has a trailing twelve months EPS of €1.62.
PE Ratio
SOCIETE GENERALE has a trailing twelve months price to earnings ratio of 15.16. Meaning, the purchaser of the share is investing €15.16 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.11%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 1.7 and the estimated forward annual dividend yield is 7.05%.
Volume
Today’s last reported volume for SOCIETE GENERALE is 418491 which is 88.33% below its average volume of 3586430.
More news about SOCIETE GENERALE.
2. ROCHE BOBOIS (RBO.PA)
65.95% Payout Ratio
Roche Bobois S.A. engages in the furniture design and distribution business worldwide. It provides living room products, such as sofas and sofa beds, coffee tables, armchairs, wall compositions, cocktail tables, TV units, bookcases, cabinets, side tables, consoles, and occasional furniture; dining room products, including chairs, stools, benches, sideboards, dining tables, columns, dressers, and dining room storage products; desks; bedroom products comprising beds, wardrobes, bedside tables, screens, complements, and other bedroom furniture products; outdoor furniture products; and lights, cushions, rugs, mirrors, decorative objects, and home furnishings, as well as other furniture products. The company offers its products under the Roche Bobois and Cuir Center brands. As of March 31, 2022, it operated 128 owned and 210 franchised stores in 56 countries worldwide, as well as an online store. The company was formerly known as Furn-Invest S.A.S. Roche Bobois S.A. was founded in 1960 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ROCHE BOBOIS has a trailing twelve months EPS of €3.
PE Ratio
ROCHE BOBOIS has a trailing twelve months price to earnings ratio of 16.17. Meaning, the purchaser of the share is investing €16.17 for every euro of annual earnings.
Volume
Today’s last reported volume for ROCHE BOBOIS is 189 which is 86.12% below its average volume of 1362.
More news about ROCHE BOBOIS.
3. SUBSEA 7 (SUBC.OL)
60.67% Payout Ratio
Subsea 7 S.A. delivers offshore projects and services for the energy industry worldwide. It provides subsea field development products and services, including project management, design and engineering, procurement, fabrication, survey, installation, and commissioning of production facilities on the seabed and the tie-back of its facilities to fixed or floating platforms or to the shore. The company also offers engineering, procurement, commissioning, and installation of subsea umbilicals, risers, and flowlines; inspection, repair, maintenance, remote intervention, and integrity management of subsea infrastructure services; conventional services comprising fabrication, installation, extension, and refurbishment of fixed and floating platforms and associated pipelines in shallow water; and hook-up services. In addition, it operates heavy lifting operations and heavy transportation services for renewables structures; and installs offshore wind turbine foundations, as well as engages in the decommissioning of redundant offshore structures. Further, the company provides remotely operated vehicles (ROVs) and tooling services to support exploration and production activities, as well as engineering and advisory services for customers in the oil and gas, renewables, and utilities industries. Subsea 7 S.A. was incorporated in 1993 and is based in Luxembourg.
Earnings Per Share
As for profitability, SUBSEA 7 has a trailing twelve months EPS of kr1.71.
PE Ratio
SUBSEA 7 has a trailing twelve months price to earnings ratio of 80.47. Meaning, the purchaser of the share is investing kr80.47 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.44%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1240% and 35.8%, respectively.
Sales Growth
SUBSEA 7’s sales growth is 8.8% for the current quarter and 5.1% for the next.
More news about SUBSEA 7.
4. FRØY (FROY.OL)
57.92% Payout Ratio
Frøy ASA provides integrated service to the aquaculture industry in Norway. The company offers wellboat services, sea freight, de-lice and treatment, mooring and laying, ring washing and cage services, inspection and certification, bottom mapping and documentation, tow, and ROV and diving services, as well as drainage, inspection, and repair services. It owns and operates 19 wellboats, 64 aqua service vessels, and 3 feed transport vessels. The company was founded in 2019 and is headquartered in Sistranda, Norway.
Earnings Per Share
As for profitability, FRØY has a trailing twelve months EPS of kr2.59.
PE Ratio
FRØY has a trailing twelve months price to earnings ratio of 29.19. Meaning, the purchaser of the share is investing kr29.19 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.67%.
Yearly Top and Bottom Value
FRØY’s stock is valued at kr75.60 at 07:10 EST, under its 52-week high of kr76.40 and way above its 52-week low of kr31.70.
Sales Growth
FRØY’s sales growth is 11.8% for the ongoing quarter and 4.1% for the next.
Moving Average
FRØY’s value is above its 50-day moving average of kr74.05 and way above its 200-day moving average of kr58.94.
More news about FRØY.
5. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.65.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.75. Meaning, the purchaser of the share is investing €14.75 for every euro of annual earnings.
Sales Growth
SANOFI’s sales growth is 1% for the ongoing quarter and negative 1.3% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 42.72.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €98.12 at 07:10 EST, below its 52-week high of €105.18 and way higher than its 52-week low of €76.45.
More news about SANOFI.
